Compare Ascendis Pharma A/S (ASND) vs Gap Inc (GAP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Gap Inc — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while Gap Inc trades at $19.41 (market cap $7.01B). The key difference: Ascendis Pharma A/S is far larger — about 2.5× Gap Inc's market cap, and Gap Inc pays a 3.6% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | GAP | |
|---|---|---|
Market Cap | $17.74B | $7.01B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $29.13 |
52-Week Low | $163.32 | $18.35 |
Enterprise Value | $18.11B | $10.09B |
Dividend Yield | — | 3.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Gap Inc. (GAP) trades at $19.46, up 3.24% today, with a bearish technical outlook but attractive valuation metrics including a P/E of 7.72 and P/S of 0.48. Recent earnings show mixed results with a Q1 2026 beat but a Q4 2025 miss. The company demonstrates strong profitability with a net income margin of 6.25% and ROE of 27.58%, supported by positive operating cash flow of $1.49 billion in 2025. News highlights include ongoing investigations by law firms and digital transformation efforts.
The stock presents a value opportunity with a consensus price target of $27.00, implying significant upside, but faces risks from legal scrutiny and competitive pressures. Analyst sentiment is mixed with 39.58% buy ratings, while technical indicators suggest near-term weakness. Revenue growth remains modest, projected at $15.4 billion for 2026, with earnings stability key to unlocking value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Gap Inc
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →
